The third big multi-agonist finished its cardiovascular safety trial
SYNCHRONIZE-CVOT, a phase 3 cardiovascular safety trial of survodutide involving 5,531 participants with overweight or obesity plus established cardiovascular disease, chronic kidney disease or multiple risk factors, reached its completion date at the end of March 2026. Two further phase 3 trials, LIVERAGE and LIVERAGE-Cirrhosis, are recruiting in the liver condition MASH, including in people with established cirrhosis.
What this actually means
Survodutide gets a fraction of the attention retatrutide does and is at a comparable stage of development. If you are trying to anticipate what reaches UK pharmacies over the next few years, it belongs on the list.
The cardiovascular outcome trial is the important one, and it is worth understanding why. These trials exist to establish that a drug which changes metabolism substantially does not cause harm somewhere unexpected. Survodutide activates the glucagon receptor, which raises blood glucose by design, so cardiovascular and metabolic safety is exactly the question that needs answering rather than a formality.
The liver trials are the more interesting bet. Testing directly in MASH, including in people who already have cirrhosis, is aiming at a condition with almost no licensed drug treatment rather than competing on weight-loss percentages.
Sources
Told first, next time
This story reached you late. A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.